Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of GS-4997 in Pulmonary Arterial Hypertension
2014-002131-34Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH), Plexogenic Pulmonary Arteriopathy, Heritable Pulmonary Arterial Hypertension (HPAH) and 1 more comparing GS-4997 dose-ranging with Placebo (2 arms). Primary endpoint: Change from baseline in pulmonary vascular resistance at Week 24. Started Feb 2015; status: terminated.
02
Drugs
selonsertib
03
Conditions
pulmonary arterial hypertension (PAH)Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)
Beyond the preview
Go deeper on 2014-002131-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002131-34.